FEMSelect is a Keiretsu Capital portfolio company that is raising a follow-on round to accelerate their growth and make what should be their last big push before an exit, which they’re already discussing with a few potential acquirers. FEMSelect developed and is commercializing a minimally invasive and meshless approach to pelvic organ prolapse repair, giving new hope to women suffering from a prevalent debilitating condition that had no good therapeutic option before FEMSelect.
